Flucloxacillin and diclofenac do not cause recurrence of neuromuscular blockade after reversal with sugammadex

Clinical Drug Investigation

Volumn 32, Issue 3, 2012, Pages 203-212

  De Kam, Pieter Jan ^a   Van Den Heuvel, Michiel W ^b   Grobara, Peter ^b   Zwiers, Alex ^b   Jadoul, Jean Luc ^c   De Clerck, Erik ^c   Ramael, Steven ^d   Peeters, Pierre A M ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ZNA Stuivenberg Sint Erasmus ^*

^c Stuivenberg General Hospital   (Belgium)

^d SGS Life Science Services   (Belgium)

Author keywords

Diclofenac; Flucloxacillin; Neuromuscular blockade; Rocuronium bromide; Sugammadex

Indexed keywords

DICLOFENAC; FLUCLOXACILLIN; PROPOFOL; ROCURONIUM; SUGAMMADEX; VECURONIUM;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR FUNCTION; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WAKEFULNESS;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; FEMALE; FLOXACILLIN; GAMMA-CYCLODEXTRINS; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR BLOCKADE; RECURRENCE;

EID: 84856897431     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11598980-000000000-00000     Document Type: Article

References (22)

1. Adam JM, Bennett DJ, Bom A, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structureactivity relationships. J Med Chem 2002; 45: 1806-16 (Pubitemid 34415376)
2. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002; 41: 266-70
3. Bom A, Epemolu O, Hope F, et al. Selective relaxant binding agents for reversal of neuromuscular blockade. Curr Opin Pharmacol 2007; 7: 298-302 (Pubitemid 46731191)
4. Jones RK, Caldwell JE, Brull SJ, et al. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008; 109: 816-24
5. Blobner M, Eriksson LI, Scholz J, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol 2010; 27: 874-81
6. Khuenl-Brady KS, Wattwil M, Vanacker BF, et al. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg 2010; 110: 64-73
7. Lemmens HJ, El-Orbany MI, Berry J, et al. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiol 2010; 10: 15
8. Uekama K, Otagiri M. Cyclodextrins in drug carrier systems. Crit Rev Ther Drug Carrier Syst 1987; 3: 1-40 (Pubitemid 17231927)
9. Zwiers A, van den Heuvel M, Smeets J, et al. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modeling approach. Clin Drug Investig 2011; 31: 101-11
10. Ploeger BA, Smeets J, Strougo A, et al. Pharmacokineticpharmacodynamic model for the reversal of neuromuscular blockade by sugammadex. Anesthesiology 2009; 110: 95-105
11. Allen SC, Ravindran D. Perioperative use of nonsteroidal anti-inflammatory drugs: results of a UK regional audit. Clin Drug Investig 2009; 29: 703-11
12. Drobnik L, Sparr HJ, Thörn SE, et al. A randomized simultaneous comparison of acceleromyography with a peripheral nerve stimulator for assessing reversal of rocuronium-induced neuromuscular blockade with sugammadex. Eur J Anaesthesiol 2010; 27: 866-73
13. de Zwart MA, Ten Bruggencate-Broeders J, van Hal HJ, et al. Determination of sugammadex in human plasma, urine, and dialysate using a high-performance liquid chromatography/ tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 1573-86
14. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007; 106: 935-43 (Pubitemid 46684059)
15. Murphy GS, Szokol JW, Marymont JH, et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg 2008; 107: 130-7
16. Fuchs-Buder T, Schreiber JU, Meistelman C. Monitoring neuromuscular block: an update. Anaesthesia 2009; 64 Suppl. 1: 82-9
17. Murphy GS, Szokol JW, Avram MJ, et al. Intraoperative acceleromyography monitoring reduces symptoms of muscle weakness and improves quality of recovery in the early postoperative period. Anesthesiology 2011; 115: 946-54
18. Fuchs-Buder T, Claudius C, Skovgaard LT, et al., 8th International Neuromuscular Meeting. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand 2007; 51: 789-808 (Pubitemid 47063004)
19. European Medicines Agency. European Public Assessment Reports: Bridion- Product Information [online]. Available from URL: 21299/SPC/ Bridion+100+mg+ml+solution+for+injection/ [Accessed 2011 Jul]
20. Duvaldestin P, Kuizenga K, Saldien V, et al. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium-or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg 2010; 110: 74-82
21. Groudine SB, Soto R, Lien C, et al. A randomized, dosefinding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007; 104: 555-62
22. Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103: 695-703 (Pubitemid 41415517)